Capricor Therapeutics Announces Continuation of Phase 3 HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis
Source:
Nasdaq GlobeNewswire
/
11 Dec 2023 09:00:00 America/New_York
N/A
Share on,